Table 2 Univariate and multivariable analyses for the risk of major bleeding
| Â | Univariate analysis | Multivariable analysis | ||
|---|---|---|---|---|
Crude OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | |
Age (per 1 year) | 1.03 (1.01–1.05) |  < 0.001 | 1.01 (0.99–1.04) | 0.17 |
Men | 0.66 (0.37–1.20) | 0.17 | 1.20 (0.63–2.29) | 0.58 |
History of major bleeding | 12.8 (4.66–35.7) |  < 0.001 | 10.8 (3.16–36.6) |  < 0.001 |
Severity of COVID-19 at admission | ||||
 Mild (Reference) | – | – | – |  |
 Moderate | 5.02 (2.22–11.4) |  < 0.001 | 1.98 (0.77–5.13) | 0.16 |
 Severe | 30.2 (13.6–67.1) |  < 0.001 | 6.15 (2.24–16.9) | 0.001 |
Pharmacological thromboprophylaxis | ||||
 No anticoagulants (Reference) | – | – | – |  |
 Prophylactic dose (LMWH or UFH) | 6.30 (2.52–15.8) |  < 0.001 | 3.02 (1.04–8.82) | 0.04 |
 Therapeutic dose (Warfarin or DOAC) | 7.69 (2.32–25.5) |  < 0.001 | 3.17 (0.84–12.0) | 0.09 |
 Therapeutic dose (UFH) | 52.7 (21.3–130.3) |  < 0.001 | 13.7 (4.27–44.2) |  < 0.001 |